In this section
@article{Trender:2024:10.1016/j.eclinm.2024.102842,
author = {Trender, W and Hellyer, P and Killingley, B and Kalinova, M and Mann, AJ and Catchpole, AP and Menon, D and Needham, E and Thwaites, R and Chiu, C and Scott, G and Hampshire, A},
doi = {10.1016/j.eclinm.2024.102842},
journal = {EClinicalMedicine},
title = {Changes in memory and cognition during the SARS-CoV-2 Human Challenge Study},
url = {http://dx.doi.org/10.1016/j.eclinm.2024.102842},
volume = {76},
year = {2024}
}
TY - JOUR
AB - BackgroundPatient-reported outcomes and cross-sectional evidence show an association between COVID-19 and persistent cognitive problems. The causal basis, longevity and domain specificity of this association is unclear due to population variability in baseline cognitive abilities, vulnerabilities, virus variants, vaccination status and treatment.MethodsThirty-four young, healthy, seronegative volunteers were inoculated with Wildtype SARS-CoV-2 under prospectively controlled conditions. Volunteers completed daily physiological measurements and computerised cognitive tasks during quarantine and follow-up at 30, 90, 180, 270, and 360 days. Linear modelling examined differences between ‘infected’ and ‘inoculated but uninfected’ individuals. The main cognitive endpoint was the baseline corrected global cognitive composite score across the battery of tasks administered to the volunteers. Exploratory cognitive endpoints included baseline corrected scores from individual tasks. The study was registered on ClinicalTrials.gov with the identifier NCT04865237 and took place between March 2021 and July 2022.FindingsEighteen volunteers developed infection by qPCR criteria of sustained viral load, one without symptoms and the remainder with mild illness. Infected volunteers showed statistically lower baseline-corrected global composite cognitive scores than uninfected volunteers, both acutely and during follow up (mean difference over all time points = −0.8631, 95% CI = −1.3613, −0.3766) with significant main effect of group in repeated measures ANOVA (F (1,34) = 7.58, p = 0.009). Sensitivity analysis replicated this cross-group difference after controlling for community upper respiratory tract infection, task-learning, remdesivir treatment, baseline reference and model structure. Memory and executive function tasks showed the largest between-group differences. No volunteers reported persistent subjective cognitive symptoms.InterpretationT
AU - Trender,W
AU - Hellyer,P
AU - Killingley,B
AU - Kalinova,M
AU - Mann,AJ
AU - Catchpole,AP
AU - Menon,D
AU - Needham,E
AU - Thwaites,R
AU - Chiu,C
AU - Scott,G
AU - Hampshire,A
DO - 10.1016/j.eclinm.2024.102842
PY - 2024///
SN - 2589-5370
TI - Changes in memory and cognition during the SARS-CoV-2 Human Challenge Study
T2 - EClinicalMedicine
UR - http://dx.doi.org/10.1016/j.eclinm.2024.102842
UR - https://www.sciencedirect.com/science/article/pii/S2589537024004218
VL - 76
ER -
